Sign In
Buy JNJ
$239.08
+7.79 (+3.37%)
At Close: Jun 23, 2026
3 Small-Cap Dividend Stocks Under $50 With Big Potential
04:10pm, Wednesday, 04'th Jun 2025
In the current market climate, investors are increasingly shifting to defensive strategies. As investors navigate the turbulent waters of tariff-driven volatility in 2025, dividend stocks have emerged
JNJ's Combo Therapy Shows Strong Phase III Efficacy in Prostate Cancer
01:20pm, Wednesday, 04'th Jun 2025
Johnson & Johnson's niraparib combo significantly delays prostate cancer progression in HRR-altered patients with strong phase III data.
3 Fortress Dividend Stocks Set to Thrive, Even if the Economy Slumps
10:10am, Wednesday, 04'th Jun 2025
These dividend stocks have solid underlying businesses. The cash flows should remain consistent regardless of the broader economic environment.
Top 3 dividend stocks to buy for 2026
10:04am, Wednesday, 04'th Jun 2025
Holding dividend stocks remains one of the most effective long-term strategies, with companies that pay a regular dividend often being profitable and well-positioned for future growth, even during eco
Johnson & Johnson (JNJ) Stock Dips While Market Gains: Key Facts
06:50pm, Tuesday, 03'rd Jun 2025
Johnson & Johnson (JNJ) closed at $154.42 in the latest trading session, marking a -0.63% move from the prior day.
I have invested in dividends for 15 years—These dividend aristocrats built my passive income stream
01:44pm, Tuesday, 03'rd Jun 2025
These Dividend Aristocrats are rock-solid businesses with a steady cash flow. They've never disappointed me and can generate a reliable paycheck each quarter.
5 Cheap Stocks to Buy in June
11:02am, Tuesday, 03'rd Jun 2025
The summer months are here, but the markets are still faced with plenty of uncertainty, so we need to remain careful about which stocks we buy.
Results from the Phase 3 AMPLITUDE study show the potential of niraparib and abiraterone acetate to delay cancer progression and worsening of symptoms1
New long-term CARTITUDE-1 data show one-third of patients treated with CARVYKTI ® remain progression-free CARTITUDE-4 analysis shows compelling overall survival and progression-free benefits in sta
Early results from Johnson & Johnson's trispecific antibody show promising response in heavily pretreated multiple myeloma patients
10:45am, Tuesday, 03'rd Jun 2025
Phase 1 trial demonstrates encouraging clinical activity of investigational immunotherapy for relapsed or refractory multiple myeloma Novel investigational dual-antigen-targeting immunotherapy binds
More than half of patients maintained minimal residual disease (MRD) negativity (10-5) with DARZALEX FASPRO ® for 24 months or longer in the Phase 3 PERSEUS study Data from Phase 3 CEPHEUS study sh
Is Merck Stock About To Crash?
08:25am, Tuesday, 03'rd Jun 2025
Why would you consider buying Johnson & Johnson stock (NYSE:JNJ) at 17 times its trailing earnings when Merck stock (NYSE: MRK) trades at around 13 times? After all, Merck has nearly 10% average reven
Johnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPC
08:00am, Tuesday, 03'rd Jun 2025
Results from the Phase 3 AMPLITUDE study show the potential of AKEEGA® (niraparib and abiraterone acetate dual-action tablet) to delay cancer progression and worsening of symptoms Data show a nearly
June's Top 10 High-Yield Stocks: Build A Path To A 10%+ Yield By 2035
04:00pm, Monday, 02'nd Jun 2025
My top 10 high-yield picks for June 2025 balance attractive dividend yields, strong financials, and competitive advantages to reduce risk and enhance returns. I use a rigorous four-step selection proc
Biotech Bull Case, ABVX International Interest, JNJ & LLY Options Trades
11:00am, Monday, 02'nd Jun 2025
"You cannot not believe in science," says Tsvetta Kaleynska. She sees biotech companies outperforming in 2025 despite a slow start to the year.
